Schrödinger taps AI to speed drug discovery
Robert Abel, chief scientific officer at Schrödinger, says advanced computational tools are changing the pace and accuracy of drug discovery. In a recent episode of The Top Line podcast, Abel…
Odyssey Therapeutics heralds $213M series D to strengthen clinical portfolio
Odyssey Therapeutics’ team of seasoned drug developers is welcoming another impressive fundraising round, closing a $213 million series D after abandoning plans to go public this summer. All of Odyssey’s…
Fierce Biotech Fundraising Tracker ’25: Arthrosi adds $153M; Expedition gears up with $165M
A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We’re maintaining the criteria we used for…
Fierce Biotech Layoff Tracker 2025: Ascidian Tx trims team; Ferring plots 500 layoffs
We hoped industry layoffs would relent in 2024. That’s not what happened. Overall, biopharma layoffs rose 3% last year compared to 2023, according to an analysis of yearly data. So,…